Board Meeting Details

The Board meeting commenced at 4:30 PM and concluded at 5:15 PM on 9th November, 2026. The Audit Committee reviewed and recommended the financial results on the same date before Board approval.

Key Approvals

1. Unaudited Standalone Financial Results: Approved for the quarter ended 30th September 2026 along with Auditors' Limited Review Report.

2. Cost Auditor Appointment: Appointed M/s V. J. Talati & Co. (Firm Regd. No. R00213) as Cost Auditors for FY 2026-27 to issue Cost Audit Report and provide guidance for maintenance of Cost Accounting Records as per Companies (Cost Records and Audit) Rules, 2014.

3. Postal Ballot Notice: Approved (details not specified in document).

Financial Performance (Quarter Ended 30th September 2026)

Income Statement (₹ lakhs):

  • Revenue from Operations: ₹7,397.20 (vs. ₹5,263.52 in Q2 FY26)
  • Other Income: ₹130.61
  • Total Income: ₹7,527.81

Expenses (₹ lakhs):

  • Cost of raw materials consumed: ₹6,581.99
  • Purchase of traded goods: ₹60.30
  • Changes in inventories: (₹538.94) [decrease]
  • Employee Benefits Expense: ₹194.04
  • Finance Costs: ₹44.88
  • Depreciation and Amortization: ₹75.29
  • Other Expenses: ₹783.22
  • Total Expenses: ₹7,200.77

Profitability (₹ lakhs):

  • Profit before Tax: ₹327.04
  • Tax Expense: ₹89.16 (Current Tax: ₹79.00, Deferred Tax: ₹10.16)
  • Profit for the period: ₹237.88
  • Other Comprehensive Income (net of tax): (₹2.77)
  • Total Comprehensive Income: ₹235.12

Earnings Per Share (EPS):

  • Basic EPS: ₹0.29 (Face value Re. 2/- per share)
  • Diluted EPS: ₹0.29

Half-Year Performance (Ended 30th September 2026)

Income Statement (₹ lakhs):

  • Revenue from Operations: ₹14,337.26 (vs. ₹9,088.67 in H1 FY26)
  • Other Income: ₹247.47
  • Total Income: ₹14,584.73

Profitability (₹ lakhs):

  • Profit before Tax: ₹661.00
  • Tax Expense: ₹171.32 (Current Tax: ₹150.00, Deferred Tax: ₹21.32)
  • Profit for the period: ₹489.68
  • Other Comprehensive Income (net of tax): (₹5.54)
  • Total Comprehensive Income: ₹484.14

Earnings Per Share (EPS):

  • Basic EPS: ₹0.59
  • Diluted EPS: ₹0.59

Balance Sheet Position (As at 30th September 2026)

Assets (₹ lakhs):

  • Total Assets: ₹20,204.14 (vs. ₹15,340.33 as of 31st March 2026)
  • Non-Current Assets: ₹2,527.77 (Property, plant and equipment: ₹1,964.70)
  • Current Assets: ₹17,676.37 (Inventories: ₹3,417.08, Trade receivables: ₹12,020.43)

Equity and Liabilities (₹ lakhs):

  • Total Equity: ₹8,031.59 (Equity share capital: ₹1,659.68, Other equity: ₹6,371.91)
  • Non-Current Liabilities: ₹459.33 (Borrowings: ₹459.33)
  • Current Liabilities: ₹11,713.22 (Borrowings: ₹2,770.52, Trade payables: ₹8,263.78)

Cash Flow Statement (Half-Year Ended 30th September 2026)

  • Net cash from operating activities: ₹432.84
  • Net cash used in investing activities: (₹238.29)
  • Net cash used in financing activities: (₹28.50)
  • Net increase in cash and equivalents: ₹166.05
  • Cash and equivalents at period end: ₹356.74

Segment Information

The company operates as a single pharmaceutical formulation manufacturing segment. Geographical revenue breakdown for Q2 FY27:

  • Sales within India: ₹3,845.90 lakh (52% of total)
  • Sales Outside India: ₹3,532.97 lakh (48% of total)
  • Total Sales: ₹7,378.87 lakh

Additional Information

  • The company has no subsidiaries, associates, or joint ventures as of 30th September 2026.
  • Previous period figures have been regrouped/reclassified for comparability.
  • Financial results are available on BSE (www.bseindia.com), NSE (www.nseindia.com), and company website (www.medicoremedies.com).
  • The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS).